Skip to NavigationSkip to content


Gilead sales soar on back of hepatitis drugs

Gilead image

The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 compared to the same period in 2013.

Both Sovaldi (sofosbuvir) and the combination treatment Harvoni (lepidasvir/sofosbuvir) were approved last year in in Europe, in January and October respectively, while Sovaldi was launched in the US in December the year before.

Shionogi and ViiV strike new HIV deal

Shionogi image

HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment.

ViiV Healthcare was established in 2009 as a joint venture between GlaxoSmithKline and Pfizer, with GSK holding an 85% stake and Pfizer taking a 15% share.

Now Shionogi will gain a 10% share in ViiV in exchange for handing over rights to the drug, integrase inhibitor dolutegravir and other early-stage drugs in the same class.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches